First-line induction chemotherapy with high-dose methotrexate versus teniposide in patients with newly diagnosed primary central nervous system lymphoma: a retrospective, multicenter cohort study
Kaili Zhong(Academy of Military Medical Sciences), Qiaohua Zhang(Shanxi Medical University), Yuhuan Gao(Hebei Medical University), Huizheng Bao(Jilin Province Tumor Hospital), Aichun Liu(Stanford University), Yuyuan Zhao(University of Liverpool), Mingzhi Zhang(Chinese Academy of Sciences), Jingwen Wang(Beijing Tongren Hospital), Mei Xue(Air Force General Hospital PLA), Yanyan Shi(Peking University), Liling Zhang(Union Hospital), Yan Qin(China University of Geosciences (Beijing)), Wei Zhang(Chinese Academy of Medical Sciences & Peking Union Medical College), Yu Yang(Chinese Academy of Sciences), Weijing Zhang(307th Hospital of Chinese People’s Liberation Army), Yan Xie(Peking University), Rong Liang(Xijing Hospital), Ningju Wang(Ningxia Medical University), Baoping Cao(People's Liberation Army No. 150 Hospital), Huilai Zhang(Shanxi Medical University), Xinan Cen(Peking University)
Cited by 7
Related Papers
Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
|Journal of Clinical Oncology|2016|1k
PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?
|Frontiers in Immunology|2017|296
Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China
|Journal of Hematology & Oncology|2017|256
Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor
|Journal of Hematology & Oncology|2016|250